KRAS and cancer: Another case where there is now a strong incentive to explore the possible involvement of iRhom2 is colorectal cancer, the second leading cause of cancer-related deaths worldwide (Bray et al., 2018; Rawla et al., 2019a), which can also be driven by oncogenic KRAS mutations (Cicenas et al., 2017).